<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30408063</article-id><article-id pub-id-type="pmc">6226108</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0206869</article-id><article-id pub-id-type="publisher-id">PONE-D-18-26427</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Loci</subject><subj-group><subject>Alleles</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Pancreatitis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genome Complexity</subject><subj-group><subject>Introns</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Complexity</subject><subj-group><subject>Introns</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Genetic Mapping</subject><subj-group><subject>Haplotypes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Hydrolases</subject><subj-group><subject>Lipases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Hydrolases</subject><subj-group><subject>Lipases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Alcoholics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Alcoholics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The common truncation variant in pancreatic lipase related protein 2 (PNLIPRP2) is expressed poorly and does not alter risk for chronic pancreatitis</article-title><alt-title alt-title-type="running-head">PNLIPRP2 truncation variant</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>N&#x000e9;meth</surname><given-names>Bal&#x000e1;zs Csaba</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Pesei</surname><given-names>Zs&#x000f3;fia Gabriella</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9137-7561</contrib-id><name><surname>Hegyi</surname><given-names>Eszter</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sz&#x000fc;cs</surname><given-names>&#x000c1;kos</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Szentesi</surname><given-names>Andrea</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hegyi</surname><given-names>P&#x000e9;ter</given-names></name><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>Mark E.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4513-9922</contrib-id><name><surname>Sahin-T&#x000f3;th</surname><given-names>Mikl&#x000f3;s</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>First Department of Medicine, University of Szeged, Szeged, Hungary</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Institute for Translational Medicine, University of P&#x000e9;cs, P&#x000e9;cs, Hungary</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>First Department of Surgery, Semmelweis University, Budapest, Hungary</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>First Department of Medicine, University of P&#x000e9;cs, P&#x000e9;cs, Hungary</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Brodsky</surname><given-names>Jeffrey L.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Pittsburgh, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>miklos@bu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>11</issue><elocation-id>e0206869</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 N&#x000e9;meth et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>N&#x000e9;meth et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0206869.pdf"/><abstract><p>A nonsense variant (p.W358X) of human pancreatic lipase related protein 2 (PNLIPRP2) is present in different ethnic populations with a high allele frequency. In cell culture experiments, the truncated protein mainly accumulates inside the cells and causes endoplasmic reticulum stress. Here, we tested the hypothesis that variant p.W358X might increase risk for chronic pancreatitis through acinar cell stress. We sequenced exon 11 of <italic>PNLIPRP2</italic> in a cohort of 256 subjects with chronic pancreatitis (152 alcoholic and 104 non-alcoholic) and 200 controls of Hungarian origin. We observed no significant difference in the distribution of the truncation variant between patients and controls. We analyzed mRNA expression in human pancreatic cDNA samples and found the variant allele markedly reduced. We conclude that the p.W358X truncation variant of <italic>PNLIPRP2</italic> is expressed poorly and has no significant effect on the risk of chronic pancreatitis.</p></abstract><funding-group><funding-statement>The studies were supported by NIH grants R01 DK082412 and R01 DK058088 (to MST), R01 DK097241 and R01 DK080820 (to MEL) and the Hungarian National Research, Development and Innovation Fund grant #FK124632 (to BCN). The registry of the Hungarian Pancreatic Study Group was supported by the Hungarian Scientific Research Fund (K116634 to PH) and the Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014 to PH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="12"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Recurrent acute pancreatitis and chronic pancreatitis are inflammatory diseases of the pancreas with significant health and economic burdens [<xref rid="pone.0206869.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0206869.ref002" ref-type="bibr">2</xref>]. After an initial episode of acute pancreatitis, 10 to 30% of adults and children have additional episodes and, of those, a large fraction develop chronic pancreatitis (CP) [<xref rid="pone.0206869.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0206869.ref004" ref-type="bibr">4</xref>]. Progression of a single episode to chronic pancreatitis often associates with genetic risk factors in genes encoding digestive enzymes expressed in pancreatic acinar cells [<xref rid="pone.0206869.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0206869.ref007" ref-type="bibr">7</xref>]. Since the discovery that a genetic variant in <italic>PRSS1</italic> (cationic trypsinogen) causes hereditary pancreatitis, most investigations to identify additional genetic risk factors focused on proteases and their inhibitors [<xref rid="pone.0206869.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0206869.ref009" ref-type="bibr">9</xref>].</p><p>More recent studies linked genetic variants in pancreatic lipases to increased risk for CP. The first report described variants in the gene encoding carboxyl ester lipase (<italic>CEL</italic>) that result in a form of autosomal dominant CP characterized by early-onset pancreatic insufficiency and diabetes [<xref rid="pone.0206869.ref010" ref-type="bibr">10</xref>]. A subsequent study found that a hybrid allele resulting from recombination of <italic>CEL</italic> and a neighboring pseudogene, <italic>CELP</italic>, increased risk for CP in northern Europeans [<xref rid="pone.0206869.ref011" ref-type="bibr">11</xref>]. Additionally, a report of two brothers who had a deficiency of pancreatic lipase (PNLIP) and evidence of CP showed they were homozygous for a missense mutation in <italic>PNLIP</italic> [<xref rid="pone.0206869.ref012" ref-type="bibr">12</xref>]. Follow-up studies indicated that the genetic variants of CEL and PNLIP likely cause disease through increased protein misfolding and maladaptive activation of unfolded protein response pathways [<xref rid="pone.0206869.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0206869.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0206869.ref015" ref-type="bibr">15</xref>]. Importantly, these studies suggest that genetic variants in other pancreatic lipases, such as the pancreatic lipase related protein 2 (PNLIPRP2), might increase the risk for CP.</p><p>PNLIPRP2 is homologous with PNLIP and both belong to the same large lipase gene family [<xref rid="pone.0206869.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0206869.ref018" ref-type="bibr">18</xref>]. Unlike PNLIP, which only digests triglycerides, PNLIPRP2 has lipase activity against triglycerides, phospholipids and galactolipids [<xref rid="pone.0206869.ref016" ref-type="bibr">16</xref>]. In newborn mice, PNLIPRP2 plays a critical role in fat digestion [<xref rid="pone.0206869.ref019" ref-type="bibr">19</xref>]. Its role in humans remains unclear. Intriguingly, a nonsense variant (p.W358X) in human <italic>PNLIPRP2</italic> is present in different ethnic populations at a high allele frequency of 0.3 to 0.5 [<xref rid="pone.0206869.ref020" ref-type="bibr">20</xref>]. When expressed in transfected HEK 293T cells, the truncated protein largely accumulated inside the cells as a detergent-insoluble aggregate and only a small amount was secreted into the medium [<xref rid="pone.0206869.ref021" ref-type="bibr">21</xref>]. The intracellular aggregates activated the unfolded protein response. The findings show that p.W358X PNLIPRP2 can alter cellular physiology through two mechanisms. First, the secretory defect results in a loss of function that might affect dietary fat digestion. Second, the intracellular aggregates of truncated PNLIPRP2 may result in a gain of function by placing pancreatic acinar cells at increased risk for injury through a maladaptive unfolded protein response. In combination with other stressors, the presence of PNLIPRP2 aggregates could activate cell death and inflammatory pathways leading to pancreatitis. A similar mechanism was reported for misfolding PRSS1 and carboxypeptidase A1 (CPA1) mutants, which appear to cause pancreatitis through endoplasmic reticulum stress [<xref rid="pone.0206869.ref022" ref-type="bibr">22</xref>]. Herein, we investigated whether the p.W358X <italic>PNLIPRP2</italic> allele is a genetic risk factor for CP in patients with alcohol-related and non-alcohol-related CP.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Nomenclature</title><p>Nucleotide numbering follows coding DNA numbering with the first nucleotide of the ATG translation initiation codon designated as +1. Amino acids are numbered starting with the initiator methionine of the primary translation product of <italic>PNLIPRP2</italic>. The NCBI genomic reference sequence for <italic>PNLIPRP2</italic> (NC_000010.11, <italic>Homo sapiens</italic> chromosome 10, GRCh38.p12 primary assembly) and the NCBI coding DNA reference sequence (NM_005396.4) correspond to the minor truncation allele. In the present study, we used the major full-length <italic>PNLIPRP2</italic> allele as reference for the designation of all <italic>PNLIPRP2</italic> variants. In this manner, the nonsense p.W358X variant becomes the &#x0201c;effect&#x0201d; allele, which is the only biologically meaningful representation. <xref rid="pone.0206869.t001" ref-type="table">Table 1</xref> compares <italic>PNLIPRP2</italic> variant designations using the two different reference sequences and lists the dbSNP numbers for unambiguous identification.</p><table-wrap id="pone.0206869.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t001</object-id><label>Table 1</label><caption><title>Designation of <italic>PNLIPRP2</italic> variants with respect to the NCBI reference sequence corresponding to the minor truncation allele and the full-length major allele used as the reference in this study.</title></caption><alternatives><graphic id="pone.0206869.t001g" xlink:href="pone.0206869.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">NCBI reference<break/>minor truncation allele</th><th align="center" colspan="2" rowspan="1">Reference used in this work<break/>major full-length allele</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic><break/>region</th><th align="center" rowspan="1" colspan="1">dbSNP<break/>number</th><th align="center" rowspan="1" colspan="1">Nucleotide<break/>change</th><th align="center" rowspan="1" colspan="1">Amino acid<break/>change</th><th align="center" rowspan="1" colspan="1">Nucleotide<break/>change</th><th align="center" rowspan="1" colspan="1">Amino acid<break/>change</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">rs4751994</td><td align="center" rowspan="1" colspan="1">c.1070-321C&#x0003e;T</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">rs4751995</td><td align="center" rowspan="1" colspan="1">c.1074A&#x0003e;G</td><td align="center" rowspan="1" colspan="1">p.X358W</td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1"><bold>p.W358X</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">rs4751996</td><td align="center" rowspan="1" colspan="1">c.1084A&#x0003e;G</td><td align="center" rowspan="1" colspan="1">p.I362V</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.V362I</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">rs10885997</td><td align="center" rowspan="1" colspan="1">c.1161A&#x0003e;G</td><td align="center" rowspan="1" colspan="1">p.S387 =</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.S387 =</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">rs7910135</td><td align="center" rowspan="1" colspan="1">c.1181+55C&#x0003e;A</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>The truncation variant is highlighted in bold type.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec004"><title>Study subjects</title><p>This study used de-identified genomic DNA samples from the registry of the Hungarian Pancreatic Study Group (ethical approval number TUKEB 22254-1/2012/EKU; biobanking approval number IF702-19/2012). Subjects were recruited from 11 Hungarian centers between 2012 and 2018 and all gave informed consent according to the ethical guidelines of the Declaration of Helsinki. The current study was also approved by the Institutional Review Board at Boston University (&#x0201c;Analysis of susceptibility genes in patients with chronic pancreatitis&#x0201d;; IRB number H-35382). A total of 256 unrelated patients with CP, including 152 with alcoholic CP and 104 with non-alcoholic CP and 200 control subjects with no pancreatic disease were analyzed. The CP study cohort included patients with a history of recurrent acute pancreatitis and/or pathological imaging findings consistent with CP, such as pancreatic calcifications, duct dilatation or irregularities, with or without exocrine pancreatic insufficiency or diabetes. Patient characteristics are described in <xref rid="pone.0206869.t002" ref-type="table">Table 2</xref>. Alcoholic CP was diagnosed in CP cases with alcohol consumption of more than 80 g/day (men) or 60 g/day (women) for at least two years. De-identified pancreatic cDNA and matching genomic DNA samples (n = 9) from cadaveric donors were obtained from the University of Szeged, Hungary.</p><table-wrap id="pone.0206869.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t002</object-id><label>Table 2</label><caption><title>Study population.</title></caption><alternatives><graphic id="pone.0206869.t002g" xlink:href="pone.0206869.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">All CP <italic>n = 256</italic></th><th align="center" colspan="2" rowspan="1">NACP n = 104</th><th align="center" colspan="2" rowspan="1">ACP n = 152</th><th align="center" colspan="2" rowspan="1">Controls <italic>n = 200</italic></th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">Female</th><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">Female</th><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">Female</th><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">Female</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>number</bold></td><td align="center" rowspan="1" colspan="1">194</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">134</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">113</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>mean age at recruitment</bold></td><td align="center" rowspan="1" colspan="1">56&#x000b1;10</td><td align="center" rowspan="1" colspan="1">56&#x000b1;14</td><td align="center" rowspan="1" colspan="1">57&#x000b1;12</td><td align="center" rowspan="1" colspan="1">57&#x000b1;16</td><td align="center" rowspan="1" colspan="1">55&#x000b1;10</td><td align="center" rowspan="1" colspan="1">53&#x000b1;9</td><td align="center" rowspan="1" colspan="1">52&#x000b1;12</td><td align="center" rowspan="1" colspan="1">52&#x000b1;13</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>mean age of disease onset</bold></td><td align="center" rowspan="1" colspan="1">48&#x000b1;12</td><td align="center" rowspan="1" colspan="1">48&#x000b1;16</td><td align="center" rowspan="1" colspan="1">47&#x000b1;12</td><td align="center" rowspan="1" colspan="1">48&#x000b1;18</td><td align="center" rowspan="1" colspan="1">48&#x000b1;12</td><td align="center" rowspan="1" colspan="1">48&#x000b1;9</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Age values indicate mean &#x000b1; S.D. in years. CP, chronic pancreatitis, NACP, non-alcoholic chronic pancreatitis, ACP, alcoholic chronic pancreatitis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec005"><title>DNA sequencing</title><p>Primer sequences and amplicon sizes are listed in <xref rid="pone.0206869.t003" ref-type="table">Table 3</xref>. PCR reactions were performed using 1.0 U HotStar Taq DNA polymerase (Qiagen, Valencia, CA), 0.2 mM dNTP, 2.0 &#x003bc;L 10x PCR buffer (Qiagen), 0.5 &#x003bc;M primers, and 10&#x02013;50 ng genomic DNA or cDNA template in a total volume of 20 &#x003bc;L. Cycling conditions were as follows: 15-min initial heat activation at 95 <sup>o</sup>C; 40 cycles of 30 s denaturation at 94 <sup>o</sup>C, 30 s annealing at 60 <sup>o</sup>C, and 60 s extension at 72 <sup>o</sup>C; and final extension for 5 min at 72 <sup>o</sup>C. Products were verified by 1.5% agarose gel electrophoresis. PCR amplicons (5 &#x003bc;L) were treated with 1 &#x003bc;L FastAP Thermosensitive Alkaline Phosphatase and 0.5 &#x003bc;L Exonuclease I (Thermo Fisher Scientific, Waltham, MA) for 15 min at 37 <sup>o</sup>C and the reaction was stopped by heating the samples to 85 <sup>o</sup>C for 15 min. Sanger sequencing was performed using the forward PCR primers as sequencing primer. Amplicons containing the heterozygous c.1070-379delG variant were also sequenced with the reverse primer.</p><table-wrap id="pone.0206869.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t003</object-id><label>Table 3</label><caption><title>Oligonucleotide primers used for PCR amplification of exon 11 of <italic>PNLIPRP2</italic> from genomic DNA (e11 primers) and a portion of the <italic>PNLIPRP2</italic> coding sequence from pancreatic cDNA (RT primers).</title></caption><alternatives><graphic id="pone.0206869.t003g" xlink:href="pone.0206869.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Primer name</th><th align="center" rowspan="1" colspan="1">Sequence (5&#x02019;&#x0003e;3&#x02019;)</th><th align="center" rowspan="1" colspan="1">Amplicon</th><th align="center" rowspan="1" colspan="1">Annealing<break/>temperature</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">PNLIPRP2 e11 forward<break/>PNLIPRP2 e11 reverse</td><td align="center" rowspan="1" colspan="1"><monospace>GTT CTG GAG GAT GGA AAT CTG</monospace><break/><monospace>CAA AAG GAG TTA GCA CAT GAC T</monospace></td><td align="center" rowspan="1" colspan="1">836 bp</td><td align="center" rowspan="1" colspan="1">60 <sup>o</sup>C</td></tr><tr><td align="center" rowspan="1" colspan="1">PNLIPRP2 RT forward<break/>PNLIPRP2 RT reverse</td><td align="center" rowspan="1" colspan="1"><monospace>CAT CTG GAT TTC TTT CCA AAT GG</monospace><break/><monospace>CGA GTG CAT TAA AGA TTT TAT TAC CG</monospace></td><td align="center" rowspan="1" colspan="1">732 bp</td><td align="center" rowspan="1" colspan="1">60 <sup>o</sup>C</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><sec id="sec007"><title>A common truncation variant in <italic>PNLIPRP2</italic></title><p>The common truncation variant c.1074G&#x0003e;A (p.W358X) in <italic>PNLIPRP2</italic> was first described in 2003 as W357X in European, African and Chinese populations with allele frequencies of 0.53, 0.55 and 0.33, respectively [<xref rid="pone.0206869.ref020" ref-type="bibr">20</xref>]. A 2010 study on the association of common gene variants and human dietary habits described the variant as W358X (rs4751995) with similar allele frequencies [<xref rid="pone.0206869.ref023" ref-type="bibr">23</xref>]. The discrepancy in numbering is because the original cloning study of <italic>PNLIPRP2</italic> missed one of the two consecutive Met codons at the start of the coding sequence [<xref rid="pone.0206869.ref018" ref-type="bibr">18</xref>]. Interestingly, the first Met is encoded by a separate upstream exon, which should be counted as exon 1 of the <italic>PNLIPRP2</italic> gene; placing the truncation variant in exon 11. The NCBI reference sequence for <italic>PNLIPRP2</italic> corresponds to the minor truncation allele. To describe the truncation variant in a biologically meaningful manner, in this study we used the major full-length <italic>PNLIPRP2</italic> allele as reference (<xref rid="pone.0206869.t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec008"><title>DNA sequence analysis of exon 11 of human <italic>PNLIPRP2</italic></title><p>We genotyped 152 subjects with alcoholic CP, 104 subjects with non-alcoholic CP and 200 control subjects, recruited from the registry of the Hungarian Pancreatic Study Group. We used direct DNA sequencing after PCR amplification of exon 11 and flanking intronic regions of <italic>PNLIPRP2</italic>. Within the amplified 793 nt sequence, we found 6 nucleotide variants, which included three intronic variants (c.1070-379delG, c.1070-321T&#x0003e;C and c.1181+55A&#x0003e;C), one synonymous variant (c.1161G&#x0003e;A, p.S387 = ), one missense variant (c.1084G&#x0003e;A, p.V362I) and the truncation variant c.1074G&#x0003e;A (p.W358X) (<xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref>). The commonly occurring variants c.1070-321T&#x0003e;C, p.W358X, p.V362I, p.S387 = and c.1181+55A&#x0003e;C were found in linkage disequilibrium as a conserved haplotype (CAAAC in <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref>). Another common haplotype (CGGAA in <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref>) was formed by variants c.1070-321T&#x0003e;C and p.S387 = .</p><fig id="pone.0206869.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.g001</object-id><label>Fig 1</label><caption><title><italic>PNLIPRP2</italic> variants in exon 11 and the flanking intronic regions identified in the present study.</title><p>The truncation variant is in bold type. The three haplotypes formed by the five commonly occurring variants are also shown.</p></caption><graphic xlink:href="pone.0206869.g001"/></fig><p>When allele frequency was considered, distribution of the variants between patients and controls showed no significant difference (<xref rid="pone.0206869.t004" ref-type="table">Table 4</xref>). Subgroup analysis for alcoholic and non-alcoholic CP patients versus controls revealed no association either (Tables <xref rid="pone.0206869.t005" ref-type="table">5</xref> and <xref rid="pone.0206869.t006" ref-type="table">6</xref>). We also analyzed genotypes using dominant and recessive models but found no significant differences in genotype frequencies between all CP patients or the alcoholic and non-alcoholic cohorts versus controls (Tables <xref rid="pone.0206869.t007" ref-type="table">7</xref>, <xref rid="pone.0206869.t008" ref-type="table">8</xref> and <xref rid="pone.0206869.t009" ref-type="table">9</xref>). Finally, comparison of the three haplotypes between patients and controls yielded no significant differences with the exception of the CGGAA haplotype (see <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref>), which was overrepresented in the non-alcoholic CP cohort relative to controls (OR 1.6, <italic>P</italic> 0.04) (Tables <xref rid="pone.0206869.t010" ref-type="table">10</xref>, <xref rid="pone.0206869.t011" ref-type="table">11</xref> and <xref rid="pone.0206869.t012" ref-type="table">12</xref>). We consider this a spurious association due to limited sample size and chance.</p><table-wrap id="pone.0206869.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t004</object-id><label>Table 4</label><caption><title>Allele frequency of <italic>PNLIPRP2</italic> variants in patients with chronic pancreatitis (CP) and controls without pancreatic disease.</title></caption><alternatives><graphic id="pone.0206869.t004g" xlink:href="pone.0206869.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Amino acid change</th><th align="center" rowspan="1" colspan="1">CP patient alleles</th><th align="center" rowspan="1" colspan="1">Control alleles</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2/512 (0.4%)</td><td align="center" rowspan="1" colspan="1">1/400 (0.3%)</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.14&#x02013;17.3</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">319/512 (62.3%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">0.84&#x02013;1.4</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1"><bold>p.W358X</bold></td><td align="center" rowspan="1" colspan="1"><bold>245/512 (47.9%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>192/400 (48%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.99</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.97</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.77&#x02013;1.3</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.V362I</td><td align="center" rowspan="1" colspan="1">245/512 (47.9%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">0.77&#x02013;1.3</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.S387 =</td><td align="center" rowspan="1" colspan="1">321/512 (62.7%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.4</td><td align="center" rowspan="1" colspan="1">0.86&#x02013;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">246/512 (48%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.77&#x02013;1.3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t005</object-id><label>Table 5</label><caption><title>Allele frequency of <italic>PNLIPRP2</italic> variants in patients with non-alcoholic chronic pancreatitis (NACP) and controls without pancreatic disease.</title></caption><alternatives><graphic id="pone.0206869.t005g" xlink:href="pone.0206869.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Amino acid change</th><th align="center" rowspan="1" colspan="1">NACP patient alleles</th><th align="center" rowspan="1" colspan="1">Control alleles</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1/208 (0.5%)</td><td align="center" rowspan="1" colspan="1">1/400 (0.3%)</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.12&#x02013;31</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">131/208 (63%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;1.6</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1"><bold>p.W358X</bold></td><td align="center" rowspan="1" colspan="1"><bold>93/208 (44.7%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>192/400 (48%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.88</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.44</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.63&#x02013;1.2</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.V362I</td><td align="center" rowspan="1" colspan="1">93/208 (44.7%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">0.63&#x02013;1.2</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.S387 =</td><td align="center" rowspan="1" colspan="1">131/208 (63%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;1.6</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">94/208 (45.2%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">0.89</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">0.64&#x02013;1.3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t006</object-id><label>Table 6</label><caption><title>Allele frequency of <italic>PNLIPRP2</italic> variants in patients with alcoholic chronic pancreatitis (ACP) and controls without pancreatic disease.</title></caption><alternatives><graphic id="pone.0206869.t006g" xlink:href="pone.0206869.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Amino acid change</th><th align="center" rowspan="1" colspan="1">ACP patient alleles</th><th align="center" rowspan="1" colspan="1">Control alleles</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1/304 (0.3%)</td><td align="center" rowspan="1" colspan="1">1/400 (0.3%)</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">0.08&#x02013;21.1</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">188/304 (61.8%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1"><bold>p.W358X</bold></td><td align="center" rowspan="1" colspan="1"><bold>152/304 (50%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>192/400 (48%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>1.1</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.6</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.8&#x02013;1.5</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.V362I</td><td align="center" rowspan="1" colspan="1">152/304 (50%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">p.S387 =</td><td align="center" rowspan="1" colspan="1">190/304 (62.5%)</td><td align="center" rowspan="1" colspan="1">240/400 (60%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.82&#x02013;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">152/304 (50%)</td><td align="center" rowspan="1" colspan="1">192/400 (48%)</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;1.5</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t006fn001"><p>The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t007</object-id><label>Table 7</label><caption><title>Genotype distribution of <italic>PNLIPRP2</italic> variants in patients with chronic pancreatitis (CP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t007g" xlink:href="pone.0206869.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">CP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1">GG<break/>delG<break/>deldel</td><td align="center" rowspan="1" colspan="1">254/256 (99.2%)<break/>2/256 (0.8%)<break/>0/256 (0%)</td><td align="center" rowspan="1" colspan="1">199/200 (99.5%)<break/>1/200 (0.5%)<break/>0/200 (0%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic>.<italic>6</italic><break/>0.78</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>72</italic><break/>0.9</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>14&#x02013;17</italic>.<italic>4</italic><break/>0.02&#x02013;39.6</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1">TT<break/>TC<break/>CC</td><td align="center" rowspan="1" colspan="1">37/256 (14.5%)<break/>119/256 (46.5%)<break/>100/256 (39%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>92</italic><break/>1.3</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>77</italic><break/>0.22</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>54&#x02013;1</italic>.<italic>6</italic><break/>0.87&#x02013;1.9</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">68/256 (26.6%)<break/>131/256 (51.2%)<break/>57/256 (22.2%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>92</italic><break/>1.1</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>7</italic><break/>0.75</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>6&#x02013;1</italic>.<italic>4</italic><break/>0.69&#x02013;1.7</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">68/256 (26.6%)<break/>131/256 (51.2%)<break/>57/256 (22.2%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>92</italic><break/>1.1</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>7</italic><break/>0.75</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>6&#x02013;1</italic>.<italic>4</italic><break/>0.69&#x02013;1.7</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">37/256 (14.5%)<break/>117/256 (45.7%)<break/>102/256 (39.8%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>92</italic><break/>1.3</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>77</italic><break/>0.16</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>54&#x02013;1</italic>.<italic>6</italic><break/>0.89&#x02013;1.9</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1">AA<break/>AC<break/>CC</td><td align="center" rowspan="1" colspan="1">68/256 (26.6%)<break/>130/256 (50.8%)<break/>58/256 (22.6%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>92</italic><break/>1.1</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>7</italic><break/>0.67</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>6&#x02013;1</italic>.<italic>4</italic><break/>0.7&#x02013;1.7</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t007fn001"><p>Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t008</object-id><label>Table 8</label><caption><title>Genotype distribution of <italic>PNLIPRP2</italic> variants in patients with non-alcoholic chronic pancreatitis (NACP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t008g" xlink:href="pone.0206869.t008"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">NACP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1">GG<break/>delG<break/>deldel</td><td align="center" rowspan="1" colspan="1">103/104 (99%)<break/>1/104 (1%)<break/>0/104 (0%)</td><td align="center" rowspan="1" colspan="1">199/200 (99.5%)<break/>1/200 (0.5%)<break/>0/200 (0%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic>.<italic>9</italic><break/>1.9</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>64</italic><break/>0.75</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>12&#x02013;31</italic>.<italic>2</italic><break/>0.04&#x02013;97.4</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1">TT<break/>TC<break/>CC</td><td align="center" rowspan="1" colspan="1">12/104 (11.5%)<break/>53/104 (51%)<break/>39/104 (37.5%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic>.<italic>2</italic><break/>1.2</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>63</italic><break/>0.49</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58&#x02013;2</italic>.<italic>5</italic><break/>0.73&#x02013;2</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">26/104 (25%)<break/>63/104 (60.6%)<break/>15/104 (14.4%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.63</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.17</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58&#x02013;1</italic>.<italic>7</italic><break/>0.33&#x02013;1.2</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">26/104 (25%)<break/>63/104 (60.6%)<break/>15/104 (14.4%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.63</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.17</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58&#x02013;1</italic>.<italic>7</italic><break/>0.33&#x02013;1.2</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">12/104 (11.5%)<break/>53/104 (51%)<break/>39/104 (37.5%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic>.<italic>2</italic><break/>1.2</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>63</italic><break/>0.49</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58&#x02013;2</italic>.<italic>5</italic><break/>0.73&#x02013;2</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1">AA<break/>AC<break/>CC</td><td align="center" rowspan="1" colspan="1">26/104 (25%)<break/>62/104 (59.6%)<break/>16/104 (15.4%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.68</td><td align="center" rowspan="1" colspan="1"><italic>1</italic><break/>0.24</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58&#x02013;1</italic>.<italic>7</italic><break/>0.36&#x02013;1.3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t008fn001"><p>Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t009" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t009</object-id><label>Table 9</label><caption><title>Genotype distribution of <italic>PNLIPRP2</italic> variants in patients with alcoholic chronic pancreatitis (ACP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t009g" xlink:href="pone.0206869.t009"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><italic>PNLIPRP2</italic></th><th align="center" rowspan="1" colspan="1">Nucleotide change</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">ACP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-379delG</td><td align="center" rowspan="1" colspan="1">GG<break/>delG<break/>deldel</td><td align="center" rowspan="1" colspan="1">151/152 (99.3%)<break/>1/152 (0.7%)<break/>0/152 (0%)</td><td align="center" rowspan="1" colspan="1">199/200 (99.5%)<break/>1/200 (0.5%)<break/>0/200 (0%)</td><td align="center" rowspan="1" colspan="1"><italic>1</italic>.<italic>3</italic><break/>1.3</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>85</italic><break/>0.89</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>08&#x02013;21</italic>.<italic>2</italic><break/>0.03&#x02013;66.6</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 10</td><td align="center" rowspan="1" colspan="1">c.1070-321T&#x0003e;C</td><td align="center" rowspan="1" colspan="1">TT<break/>TC<break/>CC</td><td align="center" rowspan="1" colspan="1">25/152 (16.5%)<break/>66/152 (43.4%)<break/>61/152 (40.1%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>79</italic><break/>1.3</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>44</italic><break/>0.2</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>44&#x02013;1</italic>.<italic>4</italic><break/>0.86&#x02013;2.1</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Exon 11</bold></td><td align="center" rowspan="1" colspan="1"><bold>c.1074G&#x0003e;A</bold></td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">42/152 (27.6%)<break/>68/152 (44.8%)<break/>42/152 (27.6%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>87</italic><break/>1.4</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58</italic><break/>0.15</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>54&#x02013;1</italic>.<italic>4</italic><break/>0.88&#x02013;2.4</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1084G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">42/152 (27.6%)<break/>68/152 (44.8%)<break/>42/152 (27.6%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>87</italic><break/>1.4</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58</italic><break/>0.15</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>54&#x02013;1</italic>.<italic>4</italic><break/>0.88&#x02013;2.4</td></tr><tr><td align="center" rowspan="1" colspan="1">Exon 11</td><td align="center" rowspan="1" colspan="1">c.1161G&#x0003e;A</td><td align="center" rowspan="1" colspan="1">GG<break/>GA<break/>AA</td><td align="center" rowspan="1" colspan="1">25/152 (16.5%)<break/>64/152 (42.1%)<break/>63/152 (41.4%)</td><td align="center" rowspan="1" colspan="1">27/200 (13.5%)<break/>106/200 (53%)<break/>67/200 (33.5%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>79</italic><break/>1.4</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>44</italic><break/>0.13</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>44&#x02013;1</italic>.<italic>4</italic><break/>0.9&#x02013;2.2</td></tr><tr><td align="center" rowspan="1" colspan="1">Intron 11</td><td align="center" rowspan="1" colspan="1">c.1181+55A&#x0003e;C</td><td align="center" rowspan="1" colspan="1">AA<break/>AC<break/>CC</td><td align="center" rowspan="1" colspan="1">42/152 (27.6%)<break/>68/152 (44.8%)<break/>42/152 (27.6%)</td><td align="center" rowspan="1" colspan="1">50/200 (25%)<break/>108/200 (54%)<break/>42/200 (21%)</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>87</italic><break/>1.4</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>58</italic><break/>0.15</td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>54&#x02013;1</italic>.<italic>4</italic><break/>0.88&#x02013;2.4</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t009fn001"><p>Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t010" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t010</object-id><label>Table 10</label><caption><title>Distribution of common <italic>PNLIPRP2</italic> haplotype alleles in patients with chronic pancreatitis (CP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t010g" xlink:href="pone.0206869.t010"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Haplotype</th><th align="center" rowspan="1" colspan="1">All CP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>CAAAC</bold></td><td align="center" rowspan="1" colspan="1"><bold>244/512 (47.7%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>191/400 (47.8%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>1</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.98</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.77&#x02013;1.3</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">CGGAA</td><td align="center" rowspan="1" colspan="1">73/512 (14.3%)</td><td align="center" rowspan="1" colspan="1">48/400 (12.0%)</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.83&#x02013;1.8</td></tr><tr><td align="center" rowspan="1" colspan="1">TGGGA</td><td align="center" rowspan="1" colspan="1">191/512 (37.3%)</td><td align="center" rowspan="1" colspan="1">160/400 (40.0%)</td><td align="center" rowspan="1" colspan="1">0.89</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">0.68&#x02013;1.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t010fn001"><p>The truncation haplotype is highlighted in bold type. OR, odds ratio; CI, confidence interval. See <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref> for more details.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t011" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t011</object-id><label>Table 11</label><caption><title>Distribution of common <italic>PNLIPRP2</italic> haplotype alleles in patients with non-alcoholic chronic pancreatitis (NACP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t011g" xlink:href="pone.0206869.t011"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Haplotype</th><th align="center" rowspan="1" colspan="1">NACP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>CAAAC</bold></td><td align="center" rowspan="1" colspan="1"><bold>92/208 (44.2%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>191/400 (47.8%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.87</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.41</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.62&#x02013;1.2</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">CGGAA</td><td align="center" rowspan="1" colspan="1">38/208 (18.3%)</td><td align="center" rowspan="1" colspan="1">48/400 (12.0%)</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.040*</td><td align="center" rowspan="1" colspan="1">1.0&#x02013;2.6</td></tr><tr><td align="center" rowspan="1" colspan="1">TGGGA</td><td align="center" rowspan="1" colspan="1">77/208 (37.0%)&#x000a0;</td><td align="center" rowspan="1" colspan="1">160/400 (40.0%)</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">0.62&#x02013;1.3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t011fn001"><p>The truncation haplotype is highlighted in bold type. OR, odds ratio; CI, confidence interval. See <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref> for more details. The asterisk indicates significant association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0206869.t012" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.t012</object-id><label>Table 12</label><caption><title>Distribution of common <italic>PNLIPRP2</italic> haplotype alleles in patients with alcoholic chronic pancreatitis (ACP) and in controls.</title></caption><alternatives><graphic id="pone.0206869.t012g" xlink:href="pone.0206869.t012"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Haplotype</th><th align="center" rowspan="1" colspan="1">ACP patients</th><th align="center" rowspan="1" colspan="1">Controls</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>CAAAC</bold></td><td align="center" rowspan="1" colspan="1"><bold>152/304 (50.0%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>191/400 (47.8%)</bold></td><td align="center" rowspan="1" colspan="1"><bold>1.1</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.55</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.81&#x02013;1.5</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">CGGAA</td><td align="center" rowspan="1" colspan="1">35/304 (11.5%)</td><td align="center" rowspan="1" colspan="1">48/400 (12.0%)</td><td align="center" rowspan="1" colspan="1">0.95</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.60&#x02013;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1">TGGGA</td><td align="center" rowspan="1" colspan="1">114/304 (37.5%)</td><td align="center" rowspan="1" colspan="1">160/400 (40.0%)</td><td align="center" rowspan="1" colspan="1">0.90</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.66&#x02013;1.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t012fn001"><p>The truncation haplotype is highlighted in bold type OR, odds ratio; CI, confidence interval. See <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref> for more details.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec009"><title>Expression of the <italic>PNLIPRP2</italic> truncation allele</title><p>To estimate the relative mRNA expression of the full-length and truncation alleles of <italic>PNLIPRP2</italic>, we used direct sequencing of pancreatic cDNA after PCR amplification of a 732 nt fragment of the coding DNA. We obtained nine de-identified cDNA samples with matching genomic DNA from cadaveric donors. Sequencing of the genomic DNA revealed five heterozygous samples and one sample homozygous for the truncation allele. The electropherograms of the heterozygous genomic sequences showed two signals at the position of variants p.W358X and p.V362I, with comparable peak heights (<xref ref-type="fig" rid="pone.0206869.g002">Fig 2A</xref>). Surprisingly, when heterozygous cDNA samples were sequenced, only one peak was visible at these positions, which corresponded to the major full-length allele, whereas no signal was apparent for the minor truncation allele (<xref ref-type="fig" rid="pone.0206869.g002">Fig 2B</xref>). PCR amplification of the pancreatic cDNA sample with the homozygous truncation allele confirmed the absence of detectable mRNA expression (<xref ref-type="fig" rid="pone.0206869.g002">Fig 2C</xref>). Taken together, our observations indicate that the truncation allele is not expressed at the mRNA level to a significant extent, in all likelihood due to nonsense-mediated mRNA decay.</p><fig id="pone.0206869.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.g002</object-id><label>Fig 2</label><caption><title>Expression of the <italic>PNLIPRP2</italic> p.W358X truncation variant.</title><p><bold>A</bold>, Electropherogram of the genomic DNA sequence of a heterozygous carrier showing the double signal at the position of variants p.W358X and p.V362I. <bold>B</bold>, Electropherogram of the pancreatic cDNA sequence of the same heterozygous subject. Note the absence of the signal corresponding to the minor truncation allele at the position of the variants. <bold>C</bold>, Agarose gel electrophoresis of PCR amplicons from pancreatic cDNA samples of subjects with homozygous A (minor truncation allele) and G (full-length allele) genotypes. Control reaction was performed with no added template.</p></caption><graphic xlink:href="pone.0206869.g002"/></fig><p>We also consulted the Genotype-Tissue Expression (GTEx) Portal (<ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org/home">www.gtexportal.org/home</ext-link>) and found that all five common variants within the truncation haplotype were associated with diminished <italic>PNLIPRP2</italic> mRNA expression (<xref ref-type="fig" rid="pone.0206869.g003">Fig 3</xref>). The GTEx database is an open-access public resource to study tissue-specific gene expression and its relationship to genetic variation. The project analyzes global RNA expression within individual human tissues from deeply genotyped donors and correlates variations in gene expression with genetic alterations.</p><fig id="pone.0206869.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0206869.g003</object-id><label>Fig 3</label><caption><title>The effect of common <italic>PNLIPRP2</italic> variants on mRNA expression in the pancreas.</title><p>Box plots were taken from the GTEx Portal (GTEx Analysis Release V7 - <ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org/">www.gtexportal.org</ext-link>). Note the diminished expression of the reference alleles (Ref), which correspond to the truncation haplotype in this database. See <xref rid="pone.0206869.t001" ref-type="table">Table 1</xref> for variant designation.</p></caption><graphic xlink:href="pone.0206869.g003"/></fig></sec></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>Physicians have increasingly recognized that CP is a complex disorder associated with multiple risk factors [<xref rid="pone.0206869.ref024" ref-type="bibr">24</xref>]. For many, particularly children, genetic variants in genes encoding pancreatic digestive enzymes contribute to the pathophysiology of CP [<xref rid="pone.0206869.ref006" ref-type="bibr">6</xref>]. In this study, we sought to determine if a common genetic variant in <italic>PNLIPRP2</italic> increased the risk for CP. The variant introduces a premature stop codon, p.W358X, resulting in a truncated protein and <italic>in vitro</italic> evidence suggests the expressed protein misfolds and activates the unfolded protein response [<xref rid="pone.0206869.ref021" ref-type="bibr">21</xref>]. We found no correlation of variant p.W358X with CP as a group or sub-grouped into alcoholic CP or non-alcoholic CP. This finding demonstrates that p.W358X is not a significant genetic risk factor for CP. We identified additional variants within exon 11 and the flanking intronic regions of <italic>PNLIPRP2</italic>, which formed conserved haplotypes. When these haplotypes were analyzed for disease association, we observed enrichment of the CGGAA haplotype (see <xref ref-type="fig" rid="pone.0206869.g001">Fig 1</xref>) in the non-alcoholic CP cohort. However, statistical significance was barely reached and we interpret this finding as fortuitous association due to the small sample size.</p><p>Because the presumed mechanism whereby variant p.W358X would contribute to CP is by activating maladaptive unfolded protein response and cell death pathways, we sought to determine if expression of the p.W358X allele was lower than expression of full length <italic>PNLIPRP2</italic>. If so, the levels of truncated protein may not be sufficient to activate the unfolded protein response. We accomplished this goal in two ways. First, we PCR amplified <italic>PNLIPRP2</italic> from pancreatic cDNA of heterozygous and homozygous p.W358X carriers and analyzed expression by DNA sequencing and agarose gel electrophoresis. Second, we interrogated the GTEx Portal database. Both methods confirmed that the amount of mRNA encoding p.W358X PNLIPRP2 is quite low compared to the mRNA amounts for full-length PNLIPRP2. The results suggest that the mRNA encoding the p.W358X variant undergoes nonsense-mediated decay [<xref rid="pone.0206869.ref025" ref-type="bibr">25</xref>]. In the previous study that characterized the cellular effects of the p.W358X variant the authors used artificial cDNA expression constructs, which lacked introns [<xref rid="pone.0206869.ref021" ref-type="bibr">21</xref>]. Consequently, the <italic>PNLIPRP2</italic> mRNA encoding the truncation variant did not suffer degradation and protein expression levels achieved were high enough to induce the unfolded protein response. The present data strongly argue that this cannot be the case when variant p.W358X is expressed from its native gene in the acinar cells.</p><p>Given the low levels of mRNA expression, it is unlikely that p.W358X PNLIPRP2 causes disease through gain-of-function as suggested by studies in transfected tissue culture cells [<xref rid="pone.0206869.ref021" ref-type="bibr">21</xref>]. In retrospect, it seems reasonable to have predicted that p.W358X PNLIPRP2 should not be a significant risk factor for CP or another disease since it is so prevalent. More likely, any effect of p.W358X PNLIPRP2 on human health should result from loss-of-function. Humans harbor many genetic variants predicted to cause loss-of-function [<xref rid="pone.0206869.ref026" ref-type="bibr">26</xref>]. Homozygosity for loss-of-function variants either results in a non-fatal phenotype or represent benign variations in redundant genes. A non-fatal loss-of-function phenotype was found in <italic>Pnliprp2</italic>-deficient mice [<xref rid="pone.0206869.ref019" ref-type="bibr">19</xref>]. Suckling <italic>Pnliprp2</italic>-deficient mice had fat malabsorption and poor growth but survived to adulthood and were fertile. It is not known if a similar effect occurs in human infants homozygous for p.W358X PNLIPRP2. In humans, p.W358X PNLIPRP2 may represent a loss-of-function tolerant genetic variant with the loss of its lipase activity compensated by other lipases [<xref rid="pone.0206869.ref016" ref-type="bibr">16</xref>]. Alternatively, p.W358X PNLIPRP2 may represent a protective or disease modifying allele [<xref rid="pone.0206869.ref027" ref-type="bibr">27</xref>]. That is, homozygosity for this allele may confer protection against disease or modify adaptations to diet [<xref rid="pone.0206869.ref023" ref-type="bibr">23</xref>]. Determination of the importance of the common p.W358X <italic>PNLIPRP2</italic> allele in human health will require additional investigations.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0206869.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>TC</given-names></name>, <name><surname>Garcea</surname><given-names>G</given-names></name>, <name><surname>Webb</surname><given-names>MA</given-names></name>, <name><surname>Al-Leswas</surname><given-names>D</given-names></name>, <name><surname>Metcalfe</surname><given-names>MS</given-names></name>, <name><surname>Dennison</surname><given-names>AR</given-names></name>. <article-title>The socio-economic impact of chronic pancreatitis: a systematic review</article-title>. <source>J Eval Clin Pract</source>
<year>2014</year>; <volume>20</volume>:<fpage>203</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1111/jep.12117</pub-id>
<pub-id pub-id-type="pmid">24661411</pub-id></mixed-citation></ref><ref id="pone.0206869.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Ting</surname><given-names>J</given-names></name>, <name><surname>Wilson</surname><given-names>L</given-names></name>, <name><surname>Schwarzenberg</surname><given-names>SJ</given-names></name>, <name><surname>Himes</surname><given-names>R</given-names></name>, <name><surname>Barth</surname><given-names>B</given-names></name>, <name><surname>Bellin</surname><given-names>MD</given-names></name>, <etal>et al</etal>
<article-title>Direct costs of acute recurrent and chronic pancreatitis in children in the INSPPIRE registry</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>2016</year>; <volume>62</volume>:<fpage>443</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0000000000001057</pub-id>
<pub-id pub-id-type="pmid">26704866</pub-id></mixed-citation></ref><ref id="pone.0206869.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bai</surname><given-names>HX</given-names></name>, <name><surname>Lowe</surname><given-names>ME</given-names></name>, <name><surname>Husain</surname><given-names>SZ</given-names></name>. <article-title>What have we learned about acute pancreatitis in children?</article-title>
<source>J Pediatr Gastroenterol Nutr</source>
<year>2011</year>; <volume>52</volume>:<fpage>262</fpage>&#x02013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e3182061d75</pub-id>
<pub-id pub-id-type="pmid">21336157</pub-id></mixed-citation></ref><ref id="pone.0206869.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Yadav</surname><given-names>D</given-names></name>, <name><surname>O'Connell</surname><given-names>M</given-names></name>, <name><surname>Papachristou</surname><given-names>GI</given-names></name>. <article-title>Natural history following the first attack of acute pancreatitis</article-title>. <source>Am J Gastroenterol</source>
<year>2012</year>; <volume>107</volume>:<fpage>1096</fpage>&#x02013;<lpage>1103</lpage>. <pub-id pub-id-type="doi">10.1038/ajg.2012.126</pub-id>
<pub-id pub-id-type="pmid">22613906</pub-id></mixed-citation></ref><ref id="pone.0206869.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Giefer</surname><given-names>MJ</given-names></name>, <name><surname>Lowe</surname><given-names>ME</given-names></name>, <name><surname>Werlin</surname><given-names>SL</given-names></name>, <name><surname>Zimmerman</surname><given-names>B</given-names></name>, <name><surname>Wilschanski</surname><given-names>M</given-names></name>, <name><surname>Troendle</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Early-onset acute recurrent and chronic pancreatitis is associated with <italic>PRSS1</italic> or <italic>CTRC</italic> gene mutations</article-title>. <source>J Pediatr</source>
<year>2017</year>; <volume>186</volume>:<fpage>95</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2017.03.063</pub-id>
<pub-id pub-id-type="pmid">28502372</pub-id></mixed-citation></ref><ref id="pone.0206869.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Schwarzenberg</surname><given-names>SJ</given-names></name>, <name><surname>Bellin</surname><given-names>M</given-names></name>, <name><surname>Husain</surname><given-names>SZ</given-names></name>, <name><surname>Ahuja</surname><given-names>M</given-names></name>, <name><surname>Barth</surname><given-names>B</given-names></name>, <name><surname>Davis</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden</article-title>. <source>J Pediatr</source>
<year>2015</year>; <volume>166</volume>:<fpage>890</fpage>&#x02013;<lpage>896</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2014.11.019</pub-id>
<pub-id pub-id-type="pmid">25556020</pub-id></mixed-citation></ref><ref id="pone.0206869.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Conwell</surname><given-names>DL</given-names></name>, <name><surname>Banks</surname><given-names>PA</given-names></name>, <name><surname>Sandhu</surname><given-names>BS</given-names></name>, <name><surname>Sherman</surname><given-names>S</given-names></name>, <name><surname>Al-Kaade</surname><given-names>S</given-names></name>, <name><surname>Gardner</surname><given-names>TB</given-names></name>, <etal>et al</etal>
<article-title>Validation of demographics, etiology, and risk factors for chronic pancreatitis in the USA: A report of the North American Pancreas Study (NAPS) Group</article-title>. <source>Dig Dis Sci</source>
<year>2017</year>; <volume>62</volume>:<fpage>2133</fpage>&#x02013;<lpage>2140</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-017-4621-z</pub-id>
<pub-id pub-id-type="pmid">28600657</pub-id></mixed-citation></ref><ref id="pone.0206869.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Whitcomb</surname><given-names>DC</given-names></name>, <name><surname>Gorry</surname><given-names>MC</given-names></name>, <name><surname>Preston</surname><given-names>RA</given-names></name>, <name><surname>Furey</surname><given-names>W</given-names></name>, <name><surname>Sossenheimer</surname><given-names>MJ</given-names></name>, <name><surname>Ulrich</surname><given-names>CD</given-names></name>, <etal>et al</etal>
<article-title>Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene</article-title>. <source>Nat Genet</source>
<year>1996</year>; <volume>14</volume>:<fpage>141</fpage>&#x02013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1038/ng1096-141</pub-id>
<pub-id pub-id-type="pmid">8841182</pub-id></mixed-citation></ref><ref id="pone.0206869.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Weiss</surname><given-names>FU</given-names></name>, <name><surname>Skube</surname><given-names>ME</given-names></name>, <name><surname>Lerch</surname><given-names>MM</given-names></name>. <article-title>Chronic pancreatitis: an update on genetic risk factors</article-title>. <source>Curr Opin Gastroenterol</source>
<year>2018</year>; <volume>34</volume>:<fpage>322</fpage>&#x02013;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1097/MOG.0000000000000461</pub-id>
<pub-id pub-id-type="pmid">29901518</pub-id></mixed-citation></ref><ref id="pone.0206869.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Raeder</surname><given-names>H</given-names></name>, <name><surname>Johansson</surname><given-names>S</given-names></name>, <name><surname>Holm</surname><given-names>PI</given-names></name>, <name><surname>Haldorsen</surname><given-names>IS</given-names></name>, <name><surname>Mas</surname><given-names>E</given-names></name>, <name><surname>Sbarra</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction</article-title>. <source>Nat Genet</source>
<year>2006</year>; <volume>38</volume>:<fpage>54</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/ng1708</pub-id>
<pub-id pub-id-type="pmid">16369531</pub-id></mixed-citation></ref><ref id="pone.0206869.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Fjeld</surname><given-names>K</given-names></name>, <name><surname>Weiss</surname><given-names>FU</given-names></name>, <name><surname>Lasher</surname><given-names>D</given-names></name>, <name><surname>Rosendahl</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>JM</given-names></name>, <name><surname>Johansson</surname><given-names>BB</given-names></name>, <etal>et al</etal>
<article-title>A recombined allele of the lipase gene <italic>CEL</italic> and its pseudogene <italic>CELP</italic> confers susceptibility to chronic pancreatitis</article-title>. <source>Nat Genet</source>
<year>2015</year>; <volume>47</volume>:<fpage>518</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3249</pub-id>
<pub-id pub-id-type="pmid">25774637</pub-id></mixed-citation></ref><ref id="pone.0206869.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Behar</surname><given-names>DM</given-names></name>, <name><surname>Basel-Vanagaite</surname><given-names>L</given-names></name>, <name><surname>Glaser</surname><given-names>F</given-names></name>, <name><surname>Kaplan</surname><given-names>M</given-names></name>, <name><surname>Tzur</surname><given-names>S</given-names></name>, <name><surname>Magal</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Identification of a novel mutation in the <italic>PNLIP</italic> gene in two brothers with congenital pancreatic lipase deficiency</article-title>. <source>J Lipid Res</source>
<year>2014</year>; <volume>55</volume>:<fpage>307</fpage>&#x02013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.P041103</pub-id>
<pub-id pub-id-type="pmid">24262094</pub-id></mixed-citation></ref><ref id="pone.0206869.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Johansson</surname><given-names>BB</given-names></name>, <name><surname>Torsvik</surname><given-names>J</given-names></name>, <name><surname>Bjorkhaug</surname><given-names>L</given-names></name>, <name><surname>Vesterhus</surname><given-names>M</given-names></name>, <name><surname>Ragvin</surname><given-names>A</given-names></name>, <name><surname>Tjora</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease</article-title>. <source>J Biol Chem</source>
<year>2011</year>; <volume>286</volume>:<fpage>34593</fpage>&#x02013;<lpage>4605</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.222679</pub-id>
<pub-id pub-id-type="pmid">21784842</pub-id></mixed-citation></ref><ref id="pone.0206869.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Szab&#x000f3;</surname><given-names>A</given-names></name>, <name><surname>Xiao</surname><given-names>X</given-names></name>, <name><surname>Haughney</surname><given-names>M</given-names></name>, <name><surname>Spector</surname><given-names>A</given-names></name>, <name><surname>Sahin-T&#x000f3;th</surname><given-names>M</given-names></name>, <name><surname>Lowe</surname><given-names>ME</given-names></name>. <article-title>A novel mutation in PNLIP causes pancreatic triglyceride lipase deficiency through protein misfolding</article-title>. <source>Biochim Biophys Acta</source>
<year>2015</year>; <volume>1852</volume>:<fpage>1372</fpage>&#x02013;<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">25862608</pub-id></mixed-citation></ref><ref id="pone.0206869.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>X</given-names></name>, <name><surname>Jones</surname><given-names>G</given-names></name>, <name><surname>Sevilla</surname><given-names>WA</given-names></name>, <name><surname>Stolz</surname><given-names>DB</given-names></name>, <name><surname>Magee</surname><given-names>KE</given-names></name>, <name><surname>Haughney</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>A carboxyl ester lipase (CEL) mutant causes chronic pancreatitis by forming intracellular aggregates that activate apoptosis</article-title>. <source>J Biol Chem</source>
<year>2016</year>; <volume>291</volume>:<fpage>23224</fpage>&#x02013;<lpage>23236</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.734384</pub-id>
<pub-id pub-id-type="pmid">27650499</pub-id></mixed-citation></ref><ref id="pone.0206869.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lowe</surname><given-names>ME</given-names></name>. <article-title>The triglyceride lipases of the pancreas</article-title>. <source>J Lipid Res</source>
<year>2002</year>; <volume>43</volume>:<fpage>2007</fpage>&#x02013;<lpage>2016</lpage>. <pub-id pub-id-type="pmid">12454260</pub-id></mixed-citation></ref><ref id="pone.0206869.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Cygler</surname><given-names>M</given-names></name>, <name><surname>Schrag</surname><given-names>JD</given-names></name>, <name><surname>Sussman</surname><given-names>JL</given-names></name>, <name><surname>Harel</surname><given-names>M</given-names></name>, <name><surname>Silman</surname><given-names>I</given-names></name>, <name><surname>Gentry</surname><given-names>MK</given-names></name>, <etal>et al</etal>
<article-title>Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins</article-title>. <source>Protein Sci</source>
<year>1993</year>; <volume>2</volume>:<fpage>366</fpage>&#x02013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1002/pro.5560020309</pub-id>
<pub-id pub-id-type="pmid">8453375</pub-id></mixed-citation></ref><ref id="pone.0206869.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Giller</surname><given-names>T</given-names></name>, <name><surname>Buchwald</surname><given-names>P</given-names></name>, <name><surname>Blum-Kaelin</surname><given-names>D</given-names></name>, <name><surname>Hunziker</surname><given-names>W</given-names></name>. <article-title>Two novel human pancreatic lipase related proteins, hPLRP1 and hPLRP2: differences in colipase dependency and in lipase activity</article-title>. <source>J Biol Chem</source>
<year>1992</year>; <volume>267</volume>:<fpage>16509</fpage>&#x02013;<lpage>16516</lpage>. <pub-id pub-id-type="pmid">1379598</pub-id></mixed-citation></ref><ref id="pone.0206869.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Lowe</surname><given-names>ME</given-names></name>, <name><surname>Kaplan</surname><given-names>MH</given-names></name>, <name><surname>Jackson-Grusby</surname><given-names>L</given-names></name>, <name><surname>D'Agostino</surname><given-names>D</given-names></name>, <name><surname>Grusby</surname><given-names>MJ</given-names></name>. <article-title>Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice</article-title>. <source>J Biol Chem</source>
<year>1998</year>; <volume>273</volume>:<fpage>31215</fpage>&#x02013;<lpage>31221</lpage>. <pub-id pub-id-type="pmid">9813028</pub-id></mixed-citation></ref><ref id="pone.0206869.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>H</given-names></name>, <name><surname>Hegele</surname><given-names>RA</given-names></name>. <article-title>DNA polymorphisms of lipase related genes</article-title>. <source>J Hum Genet</source>
<year>2003</year>;<volume>48</volume>:<fpage>443</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1007/s10038-003-0051-1</pub-id>
<pub-id pub-id-type="pmid">12898288</pub-id></mixed-citation></ref><ref id="pone.0206869.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>X</given-names></name>, <name><surname>Mukherjee</surname><given-names>A</given-names></name>, <name><surname>Ross</surname><given-names>LE</given-names></name>, <name><surname>Lowe</surname><given-names>ME</given-names></name>. <article-title>Pancreatic lipase-related protein-2 (PLRP2) can contribute to dietary fat digestion in human newborns</article-title>. <source>J Biol Chem</source>
<year>2011</year>; <volume>286</volume>:<fpage>26353</fpage>&#x02013;<lpage>26363</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.249813</pub-id>
<pub-id pub-id-type="pmid">21652702</pub-id></mixed-citation></ref><ref id="pone.0206869.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Sahin-T&#x000f3;th</surname><given-names>M</given-names></name>. <article-title>Genetic risk in chronic pancreatitis: the misfolding-dependent pathway</article-title>. <source>Curr Opin Gastroenterol</source>
<year>2017</year>; <volume>33</volume>:<fpage>390</fpage>&#x02013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1097/MOG.0000000000000380</pub-id>
<pub-id pub-id-type="pmid">28650851</pub-id></mixed-citation></ref><ref id="pone.0206869.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Hancock</surname><given-names>AM</given-names></name>, <name><surname>Witonsky</surname><given-names>DB</given-names></name>, <name><surname>Ehler</surname><given-names>E</given-names></name>, <name><surname>Alkorta-Aranburu</surname><given-names>G</given-names></name>, <name><surname>Beall</surname><given-names>C</given-names></name>, <name><surname>Gebremedhin</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Colloquium paper: human adaptations to diet, subsistence, and ecoregion are due to subtle shifts in allele frequency</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2010</year>;<volume>107</volume> Suppl <issue>2</issue>:<fpage>8924</fpage>&#x02013;<lpage>8930</lpage>.<pub-id pub-id-type="pmid">20445095</pub-id></mixed-citation></ref><ref id="pone.0206869.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kleeff</surname><given-names>J</given-names></name>, <name><surname>Whitcomb</surname><given-names>DC</given-names></name>, <name><surname>Shimosegawa</surname><given-names>T</given-names></name>, <name><surname>Esposito</surname><given-names>I</given-names></name>, <name><surname>Lerch</surname><given-names>MM</given-names></name>, <name><surname>Gress</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Chronic pancreatitis</article-title>. <source>Nat Rev Dis Primers</source>
<year>2017</year>; <volume>3</volume>:<fpage>17060</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2017.60</pub-id>
<pub-id pub-id-type="pmid">28880010</pub-id></mixed-citation></ref><ref id="pone.0206869.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Lykke-Andersen</surname><given-names>S</given-names></name>, <name><surname>Jensen</surname><given-names>TH</given-names></name>. <article-title>Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes</article-title>. <source>Nat Rev Mol Cell Biol</source>
<year>2015</year>; <volume>16</volume>:<fpage>665</fpage>&#x02013;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1038/nrm4063</pub-id>
<pub-id pub-id-type="pmid">26397022</pub-id></mixed-citation></ref><ref id="pone.0206869.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>MacArthur</surname><given-names>DG</given-names></name>, <name><surname>Balasubramanian</surname><given-names>S</given-names></name>, <name><surname>Frankish</surname><given-names>A</given-names></name>, <name><surname>Huang</surname><given-names>N</given-names></name>, <name><surname>Morris</surname><given-names>J</given-names></name>, <name><surname>Walter</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>A systematic survey of loss-of-function variants in human protein-coding genes</article-title>. <source>Science</source>
<year>2012</year>; <volume>335</volume>:<fpage>823</fpage>&#x02013;<lpage>828</lpage>. <pub-id pub-id-type="doi">10.1126/science.1215040</pub-id>
<pub-id pub-id-type="pmid">22344438</pub-id></mixed-citation></ref><ref id="pone.0206869.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Harper</surname><given-names>AR</given-names></name>, <name><surname>Nayee</surname><given-names>S</given-names></name>, <name><surname>Topol</surname><given-names>EJ</given-names></name>. <article-title>Protective alleles and modifier variants in human health and disease</article-title>. <source>Nat Rev Genet</source>
<year>2015</year>; <volume>16</volume>:<fpage>689</fpage>&#x02013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1038/nrg4017</pub-id>
<pub-id pub-id-type="pmid">26503796</pub-id></mixed-citation></ref></ref-list></back></article>